Funding concerns temper industry welcome for UK early access scheme, new drug designation
This article was originally published in SRA
Executive Summary
The UK's long-awaited early access to medicines scheme (EAMS) is to be launched in April along with a new "promising innovative medicine" (PIM) designation that the government says will both give patients timely access to new drugs for serious diseases before they are approved and help companies secure investment for drugs under development at an earlier stage in the process1.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.